Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH): Time To Buy Over The Next Few Months

In the last trading session, 1.29 million Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) shares changed hands as the company’s beta touched 0.02. With the company’s per share price at $4.01 changed hands at -$0.56 or -12.35% during last session, the market valuation stood at $90.83M. RVPH’s last price was a discount, traded about -130.67% off its 52-week high of $9.25. The share price had its 52-week low at $3.03, which suggests the last value was 24.44% up since then. When we look at Reviva Pharmaceuticals Holdings Inc.’s average trading volume, we note the 10-day average is 0.71 million shares, with the 3-month average coming to 1.06 million.

Analysts gave the Reviva Pharmaceuticals Holdings Inc. (RVPH) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RVPH as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Reviva Pharmaceuticals Holdings Inc.’s EPS for the current quarter is expected to be $Reviva Pharmaceuticals Holdings.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) trade information

Instantly RVPH was in red as seen at the end of in last trading. With action -30.26%, the performance over the past five days has been red. The drop to weekly highs of 6.30 on Friday, 11/17/23 subtracted -12.35% to the stock’s daily price. The company’s shares are showing year-to-date downside of -5.65%, with the 5-day performance at -30.26% in the red. However, in the 30-day time frame, Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) is 8.09% up. Looking at the short shares, we see there were 2.53 million shares sold at short interest cover period of 1.02 days.

The consensus price target for the stock as assigned by Wall Street analysts is $16.83, meaning bulls need an upside of 76.17% from its current market value. According to analyst projections, RVPH’s forecast low is $12.00 with $20.00 as the target high. To hit the forecast high, the stock’s price needs a -398.75% plunge from its current level, while the stock would need to soar -199.25% for it to hit the projected low.

Reviva Pharmaceuticals Holdings Inc. (RVPH) estimates and forecasts

Data shows that the Reviva Pharmaceuticals Holdings Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -45.07% over the past 6 months, a -12.80% in annual growth rate that is considerably lower than the industry average of 11.30%.

The 2023 estimates are for Reviva Pharmaceuticals Holdings Inc. earnings to decrease by -17.60%.

RVPH Dividends

Reviva Pharmaceuticals Holdings Inc. is expected to release its next quarterly earnings report on November 14.

Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 21.86% of Reviva Pharmaceuticals Holdings Inc. shares while 6.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 7.77%. There are 6.07% institutions holding the Reviva Pharmaceuticals Holdings Inc. stock share, with Armistice Capital, LLC the top institutional holder. As of Jun 29, 2023, the company held 3.64% of the shares, roughly 0.82 million RVPH shares worth $4.83 million.

Vanguard Group Inc holds the second largest percentage of outstanding shares, with 2.72% or 0.62 million shares worth $3.61 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.37 million shares estimated at $2.18 million under it, the former controlled 1.64% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.98% of the shares, roughly 0.22 million shares worth around $1.3 million.

On Key

Related Posts